Actively Recruiting
Prospectively Collected Pleural Biopsies for Validation of Malignant Pleural Mesothelioma Prognostic Biomarkers
Led by Dana-Farber Cancer Institute · Updated on 2026-05-05
240
Participants Needed
1
Research Sites
621 weeks
Total Duration
On this page
Sponsors
D
Dana-Farber Cancer Institute
Lead Sponsor
N
National Cancer Institute (NCI)
Collaborating Sponsor
AI-Summary
What this Trial Is About
This research study is evaluating a new method for determining stage and prognosis of individuals with malignant pleural mesothelioma.
CONDITIONS
Official Title
Prospectively Collected Pleural Biopsies for Validation of Malignant Pleural Mesothelioma Prognostic Biomarkers
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults aged 18 years or older
- Diagnosed with malignant pleural mesothelioma
- Undergoing diagnostic pleural biopsy, pleuroscopy, or VATS resections
You will not qualify if you...
- Patients unsuitable for surgery
- Patients unsuitable for treatment
- Patients unsuitable for diagnosis
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Brigham and Women's Hospital
Boston, Massachusetts, United States, 02215
Actively Recruiting
Research Team
R
Raphael Bueno, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here